Posted On: 08/30/2014 10:37:30 AM
Post# of 30066
We should all stick to what was stated in the PR and not let our expectations get carried away (again). Here's what to expect on the business update call, as given by the August 27 PR.
There is nothing stated about a LymPro partnership or LP-002 data being disclosed. Those updates will come when they are ready, and not before. This is not directed at you, Maui, but all of us who have high hopes and sometimes let our expectations run wild.
Quote:
The Company anticipates addressing a number of matters related to our core programs, including:
• qualitative early revenue guidance for LymPro
• progress being made on the Company's Phase 2b initiation with Eltoprazine for PD LID, and
• next steps toward a first-in-man trial for MANF in orphan ophthalmological indications
There is nothing stated about a LymPro partnership or LP-002 data being disclosed. Those updates will come when they are ready, and not before. This is not directed at you, Maui, but all of us who have high hopes and sometimes let our expectations run wild.
(0)
(0)
